View ValuationAvenir Wellness Solutions 将来の成長Future 基準チェック /06現在、 Avenir Wellness Solutionsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Aug 17Avenir Wellness Solutions, Inc. Provides Sales Guidance for the Second Half of 2023Avenir Wellness Solutions, Inc. provided sales guidance for the second half of 2023. For the period, sales are expected to increase.すべての更新を表示Recent updatesお知らせ • Apr 02Avenir Wellness Solutions, Inc. announced delayed annual 10-K filingOn 04/01/2025, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 16Avenir Wellness Solutions, Inc. announced delayed 10-Q filingOn 11/15/2024, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Avenir Wellness Solutions, Inc. announced delayed 10-Q filingOn 05/16/2024, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Avenir Wellness Solutions, Inc. announced delayed annual 10-K filingOn 04/01/2024, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 17Avenir Wellness Solutions, Inc. Provides Sales Guidance for the Second Half of 2023Avenir Wellness Solutions, Inc. provided sales guidance for the second half of 2023. For the period, sales are expected to increase.New Risk • Jun 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.68m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$10m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$173k). Earnings have declined by 17% per year over the past 5 years. Market cap is less than US$10m (US$9.68m market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (11% increase in shares outstanding).お知らせ • May 16Avenir Wellness Solutions, Inc. announced delayed 10-Q filingOn 05/15/2023, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 20Avenir Wellness Solutions to Launch Wall Street-Focused Informational Series with Producer New to the StreetAvenir Wellness Solutions, Inc. announced that it is launching an informational series to inform the Wall Street community about its unique dual revenue model involving breakthrough consumer wellness products and intellectual property monetization. Avenir has retained producer New to The Street to create sponsored television content featuring Avenir's leadership that will be nationally and internationally syndicated on major television networks. Avenir's management will introduce themselves to New to The Street's viewers and provide updates about the Company's science-based delivery systems for their wellness, skincare/beauty, and new market disruptive products. Filmed discussions will occur at the on-site studios, New York Stock Exchange,Nasdaq MarketSite, or off-site through Zoom video calls. Each segment is to air across New to The Street's syndicated televised platforms on Newsmax TV and FOX Business Network, and as a sponsored program on Bloomberg TV. New to The Street expects each televised airing to bring attention to Avenir's operations and how they are developing new cutting-edge technologies and building the foundation of the Company. Avenir has uniquely positioned itself to enhance its market share within its multi-billion-dollar industry.お知らせ • Nov 15CURE Pharmaceutical Holding Corp. announced delayed 10-Q filingOn 11/14/2022, CURE Pharmaceutical Holding Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 17+ 1 more updateCURE Pharmaceutical Holding Corp. announced delayed 10-Q filingOn 08/16/2022, CURE Pharmaceutical Holding Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 03CURE Pharmaceutical Holding Corp. Appoints Gerald Bagg to Its Board of DirectorsCURE Pharmaceutical Holding Corp. announced the appointment of Gerald Bagg to its board of directors. This strategic addition adds depth in CPG and advertising and brings the number of board members to five. A 45+ year veteran of the advertising industry, Gerald is best known for pioneering the BRAND RESPONSE advertising approach to campaigns. Gerald is the Chairman and a co-founder of Quigley-Simpson & Heppelwhite Inc. Prior to establishing Quigley-Simpson, Gerald had an extensive advertising and marketing career beginning in 1976. Gerald’s distinguished career has included senior executive positions with major advertising agencies and retailers.お知らせ • Apr 03CURE Pharmaceutical Holding Corp. announced delayed annual 10-K filingOn 04/01/2022, CURE Pharmaceutical Holding Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 05CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in MexicoCure Pharmaceutical and Milagro Pharmaceuticals announced their collaboration to register and sell in Mexico a number of CURE’s OTC and medical compounds that utilize CUREform, CURE’s patented drug delivery platform for oral thin film. Cure is in discussions with several large distributors in Mexico and Latin America. OTF products that will be marketed and sold in Mexico via key distribution partners include CUREfilm Blue - an oral soluble form of sildenafil citrate for the treatment of erectile dysfunction. Vitamin D3 - that provides a convenient, weekly 40,000 IU dose of Vitamin D An electrolyte energy boost - that provides a healthier, sugar-free alternative to energy drinks Sleep - a dose of melatonin that dissolves on the tongue so it can be taken even after the user climb into bed. The opportunity to serve the Latin American market with this venture into Mexico is an exciting one that is expected to accelerate the ramp up of CURE’s FDA-registered, cGMP manufacturing facility, where the Company pioneered and developed its patented CUREfilm, drug delivery platform. The Company expects to select a distribution partner for the LATAM territory in the coming months.お知らせ • Mar 17CURE Pharmaceutical Holding Corp. Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health DisordersCURE Pharmaceutical Holding Corp. announced that it has launched a new initiative for the clinical development of psychedelic compounds such as psilocybin, LSD, and MDMA for the treatment of various mental health disorders. Utilizing CURE’s patented oral film platform CUREfilm for precision dosing, the company intends to optimize the absorption and metabolism of psychedelic actives targeting clinical efficacy of both macrodosing and microdosing treatment regimens. CURE will use its DEA Schedule 1 license and cGMP-certified and FDA-registered facility providing a United States footprint for anticipated commercialization. Ongoing research, which has been active for decades, continues to showcase a growing body of evidence in support of psychedelics as effective treatments for mental health disorders such as depression, PTSD, addiction disorders, obsessive compulsive disorder, and anxiety.お知らせ • Mar 12CURE Pharmaceutical Holding Corp. Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral ApplicationsCURE Pharmaceutical Holding Corp. announced that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline. The first is an antiviral clinical development program where the Company will look to load a known active pharmaceutical ingredient (API) onto its patented drug delivery platform CUREfilm®, CURE’s oral thin film platform that optimizes the absorption and metabolism of therapeutic actives. The second pipeline product addition uses a similar bioequivalence approach where the Company will formulate the delivery of a known anti-seizure API for both adult and pediatric indications. These programs will leverage existing pre-clinical/clinical safety and toxicity data to develop orally bioavailable products and expand the Company’s pharmaceutical research & development efforts toward building a specialty pharmaceutical pipeline. CURE recently announced the start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Sildenafil Citrate oral dispersible product known as CUREfilm® blue. This application, as well as these additional pipeline products are anticipated to be initiated via the 505(b)(2) drug approval pathway, with both Academic and Industry partnerships anticipated to facilitate the most intuitive path to commercialization.お知らせ • Feb 24CURE Pharmaceutical Announces the Initiation of Clinical Trials for Erectile Dysfunction Product Curefilm Blue™CURE Pharmaceutical Holding Corp. announced this week’s start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). This application has been initiated via the 505(b)(2) drug approval pathway, and is in continuation of FDA-provided feedback in support of CURE’s clinical development plans for its CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience. The global erectile dysfunction drug market is projected to reach approximately $6.6 Billion by 2025, at a CAGR of 6.0% over the five-year forecasted period with sildenafil representing a majority of the market according to a report by QYR Research.お知らせ • Feb 12CURE Pharmaceutical Holdings Announces Promotions and Additions to Board of DirectorsCURE Pharmaceutical Holdings announced updates and additions to its Board of Directors. After a dedicated run as Chairman of the Board, William Yuan is stepping down and will continue to serve the Company as an advisor and Chairman Emeritus. Rubén José King-Shaw Jr, a highly qualified and respected member of the Board, has been selected to step into that role. Mr. King-Shaw brings with him three decades of executive leadership experience in the healthcare technology and private equity sectors. He recently served on the board of Atlanta-based Cotiviti Holdings Inc. and currently serves on the board of US Retina of Denver, CO. He is currently serving as Chief Strategy Officer of Steward Health Care Systems, LLC, and has held C-suite positions with leading private companies including Neighborhood Health Partnership Inc. and JMH Health Plan.お知らせ • Jan 06Cure Pharmaceutical Receives Fda Approval for Its Ind Application for Erectile Dysfunction Product Curefilm Blue™CURE Pharmaceutical Holding Corp. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience.お知らせ • Oct 30CURE Pharmaceutical Holding Corp. Appoints Nancy Duitch to the BoardEffective October 23, 2020, the Board of Directors of Cure Pharmaceutical Holding Corp. (the “Company”), appointed Nancy Duitch as a new member of the Board pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 23, 2020 (the “Merger Agreement”), by and among the Company, Cure Labs Inc., and The Sera Labs Inc., and Nancy Duitch, in her capacity as the security holders representative. On October 5, 2020, as a condition to closing the Merger, the Company entered into an employment agreement with Ms. Duitch as Chief Strategy Officer-Wellness of the Company.お知らせ • Oct 06+ 1 more updateCURE Pharmaceutical Holding Corp. (OTCPK:CURR) completed the acquisition of Sera Labs, Inc.CURE Pharmaceutical Holding Corp. (OTCPK:CURR) entered into a non-binding Memorandum of Understanding to acquire Sera Labs, Inc. for $44 million on July 27, 2020. CURE Pharmaceutical Holding Corp. entered into a definitive agreement to acquire Sera Labs, Inc. on September 23, 2020. The consideration is comprised of $19 million in CURE stock at a valuation of $2.75 per share and $1 million in cash, with an initial, additional commitment of $4 million for working capital in support of accelerating Sera Labs’ growth. The transaction also includes the potential for an earn out of up to $20 million in CURE stock at a valuation of $3.34 per share within two years of the closing of the acquisition, contingent upon Sera Labs achieving certain key financial targets. Pursuant to the transaction, Sera Labs will become a wholly-owned subsidiary of the company. In connection with the execution of the Memorandum of Understanding, the company will loan to Sera Labs $500,000 in exchange for the issuance of a secured promissory note, with the right to take a future advance of an additional $1,000,000 if the Proposed Acquisition does not close by September 1, 2020. The Promissory Note is secured by certain assets of Sera Labs. The Promissory Note bears an interest rate of 9% per annum and has a maturity date of December 31, 2020. The outstanding principal amount and any unpaid accrued interest may be prepaid at any time, provided that Sera Labs gives written notice to the company at least 15 days in advance of the prepayment. The Promissory Note provides that, upon the occurrence of any Event of Default, the company may accelerate the Promissory Note by written notice to Sera Labs, with the principal amount plus all accrued but unpaid interest becoming immediately due and payable in cash, except that, upon the occurrence of a Bankruptcy Event, no notice shall be required and the Outstanding Balance shall become immediately and automatically due and payable. The Promissory Note further provides that if a merger transaction is effected between the company and Sera Labs pursuant to the terms of a definitive merger agreement, the outstanding principal amount shall be credited to marketing and growth funds, as to be described in such definitive merger agreement. Sera Labs and CURE teams will be joining forces and Nancy Duitch, founder and Chief Executive Officer of Sera Labs, will continue leadership at the helm of Sera Labs and will also serve as a key member of CURE‘s leadership team upon closing of the transaction. The transaction is expected to close, subject to a definitive agreement and customary closing conditions, by the fourth quarter of 2020. As of September 24, 2020, the transaction is expected to close in early October. CURE Pharmaceutical Holding Corp. (OTCPK:CURR) completed the acquisition of Sera Labs, Inc. on October 2, 2020. At the Effective Time of the Merger, all issued and outstanding shares of the capital stock of Sera Labs were converted into the right to receive, subject to customary adjustments, an aggregate of approximately $1 million in cash and up to 6,.9 million shares of the CURE Pharmaceutical Holding Corp.'s common stock. On October 1, 2020, CURE Pharmaceutical and Sera Labs entered into a Waiver of closing condition, pursuant to which the CURE Pharmaceutical's obligation to pay the upfront payment at the effective time was extended to October 13, 2020. Pursuant to the Merger Agreement, Sera Labs security holders are also entitled to receive up to 5.9 million shares of the CURE Pharmaceutical's common stock based on the achievement of certain sales milestones up to an aggregate maximum amount of $20 million as set forth in the merger agreement. In connection with the merger the transaction is subject to lock-Up agreement, escrow agreement, ancillary agreement and employment agreement. The transaction is also subject to CURE Pharmaceutical's stock holders. Brent A. Reinke from Musick Peeler & Garrett LLP served as a legal advisor for CURE Pharmaceutical Holding Corp. Rick Citron from Citron & Deutsch served as a legal advisor for Sera Labs, Inc. and Nancy Duitch.お知らせ • Oct 01CURE Pharmaceutical Holding Corp. announced that it has received $1 million in funding from Ionic Ventures, LLCCURE Pharmaceutical Holding Corp. (OTCPK:CURR) announced a private placement of demand secured promissory note for principal amount of $1,100,000 receiving gross proceeds of $1,000,000 on September 25, 2020. The transaction included participation from Ionic Ventures, LLC. The promissory note are issued at $100,000 original discount. The notes bears no interest rate and is subject to payment on demand of the investor after the earlier of either the initial date after September 25, 2020 of any offering of securities by the company with gross proceeds of at least $1,000,000 or October 31, 2020.お知らせ • Sep 30Cure Pharmaceutical Holding Corp. to Enter into an Employment Agreement with Nancy Duitch in Her Capacity as Chief Strategy Officer - WellnessOn September 23, 2020, Cure Pharmaceutical Holding Corp. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization by and among the Company, Cure Labs Inc., a Delaware corporation and a wholly owned, subsidiary of the Company (“Merger Sub”), The Sera Labs Inc., a Delaware corporation (“Sera Labs”), and Nancy Duitch, in her capacity as the security holders representative. The Merger Agreement provides for the acquisition of Sera Labs by the Company through the merger of Merger Sub with and into Sera Labs, with Sera Labs surviving as a wholly owned, subsidiary of the Company (the “Merger”). The Merger Agreement also contemplates that at the Effective Time the Company will enter into an employment agreement with Nancy Duitch in her capacity as Chief Strategy Officer - Wellness of the Company and Chief Executive Officer of Sera Labs.お知らせ • Sep 26Cure Pharmaceutical Holding Corp. Announces Appointments to its BoardCure Pharmaceutical Holding Corp. at its AGM held on September 23, 2020 announced appointment of Gene Salkind and Lauren Chung to the Board of Directors, each for a one-year term ending at the Annual Meeting of Stockholders to be held in 2021 and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Avenir Wellness Solutions は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:AVRW - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20242-3-2-2N/A6/30/20243-4-2-2N/A3/31/20244-5-3-3N/A12/31/20234-3-4-4N/A9/30/20234-11-5-5N/A6/30/20235-5-9-9N/A3/31/20235-14-6-6N/A12/31/20225-19-10-10N/A9/30/20225-14-10-10N/A6/30/20225-21-7-7N/A3/31/20226-11-8-8N/A12/31/20216-9-4-4N/A9/30/20216-23-7-7N/A6/30/20215-22-7-7N/A3/31/20213-36-10-10N/A12/31/20202-31-10-10N/A9/30/20201-15-8-7N/A6/30/20201-10-8-7N/A3/31/20201-9-10-9N/A12/31/20191-21-9-8N/A9/30/20191-22-8-7N/A6/30/20191-29-7-6N/A3/31/20191-19-4-4N/A12/31/20181-10-4-4N/A9/30/20180-10-4-4N/A6/30/20180-7N/A-4N/A3/31/20180-7N/A-4N/A12/31/20170-8N/A-4N/A9/30/20170-9N/A-4N/A6/30/20170-8N/A-4N/A3/31/20170-6N/A-3N/A12/31/20160-4N/A-4N/A9/30/20160-2N/A-3N/A6/30/20160-2N/A-2N/A3/31/20160-2N/A-1N/A12/31/20150-2N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AVRWの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: AVRWの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: AVRWの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: AVRWの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: AVRWの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AVRWの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 13:52終値2026/05/13 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Avenir Wellness Solutions, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 17Avenir Wellness Solutions, Inc. Provides Sales Guidance for the Second Half of 2023Avenir Wellness Solutions, Inc. provided sales guidance for the second half of 2023. For the period, sales are expected to increase.
お知らせ • Apr 02Avenir Wellness Solutions, Inc. announced delayed annual 10-K filingOn 04/01/2025, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 16Avenir Wellness Solutions, Inc. announced delayed 10-Q filingOn 11/15/2024, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Avenir Wellness Solutions, Inc. announced delayed 10-Q filingOn 05/16/2024, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Avenir Wellness Solutions, Inc. announced delayed annual 10-K filingOn 04/01/2024, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 17Avenir Wellness Solutions, Inc. Provides Sales Guidance for the Second Half of 2023Avenir Wellness Solutions, Inc. provided sales guidance for the second half of 2023. For the period, sales are expected to increase.
New Risk • Jun 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.68m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$10m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$173k). Earnings have declined by 17% per year over the past 5 years. Market cap is less than US$10m (US$9.68m market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (11% increase in shares outstanding).
お知らせ • May 16Avenir Wellness Solutions, Inc. announced delayed 10-Q filingOn 05/15/2023, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 20Avenir Wellness Solutions to Launch Wall Street-Focused Informational Series with Producer New to the StreetAvenir Wellness Solutions, Inc. announced that it is launching an informational series to inform the Wall Street community about its unique dual revenue model involving breakthrough consumer wellness products and intellectual property monetization. Avenir has retained producer New to The Street to create sponsored television content featuring Avenir's leadership that will be nationally and internationally syndicated on major television networks. Avenir's management will introduce themselves to New to The Street's viewers and provide updates about the Company's science-based delivery systems for their wellness, skincare/beauty, and new market disruptive products. Filmed discussions will occur at the on-site studios, New York Stock Exchange,Nasdaq MarketSite, or off-site through Zoom video calls. Each segment is to air across New to The Street's syndicated televised platforms on Newsmax TV and FOX Business Network, and as a sponsored program on Bloomberg TV. New to The Street expects each televised airing to bring attention to Avenir's operations and how they are developing new cutting-edge technologies and building the foundation of the Company. Avenir has uniquely positioned itself to enhance its market share within its multi-billion-dollar industry.
お知らせ • Nov 15CURE Pharmaceutical Holding Corp. announced delayed 10-Q filingOn 11/14/2022, CURE Pharmaceutical Holding Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 17+ 1 more updateCURE Pharmaceutical Holding Corp. announced delayed 10-Q filingOn 08/16/2022, CURE Pharmaceutical Holding Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 03CURE Pharmaceutical Holding Corp. Appoints Gerald Bagg to Its Board of DirectorsCURE Pharmaceutical Holding Corp. announced the appointment of Gerald Bagg to its board of directors. This strategic addition adds depth in CPG and advertising and brings the number of board members to five. A 45+ year veteran of the advertising industry, Gerald is best known for pioneering the BRAND RESPONSE advertising approach to campaigns. Gerald is the Chairman and a co-founder of Quigley-Simpson & Heppelwhite Inc. Prior to establishing Quigley-Simpson, Gerald had an extensive advertising and marketing career beginning in 1976. Gerald’s distinguished career has included senior executive positions with major advertising agencies and retailers.
お知らせ • Apr 03CURE Pharmaceutical Holding Corp. announced delayed annual 10-K filingOn 04/01/2022, CURE Pharmaceutical Holding Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 05CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in MexicoCure Pharmaceutical and Milagro Pharmaceuticals announced their collaboration to register and sell in Mexico a number of CURE’s OTC and medical compounds that utilize CUREform, CURE’s patented drug delivery platform for oral thin film. Cure is in discussions with several large distributors in Mexico and Latin America. OTF products that will be marketed and sold in Mexico via key distribution partners include CUREfilm Blue - an oral soluble form of sildenafil citrate for the treatment of erectile dysfunction. Vitamin D3 - that provides a convenient, weekly 40,000 IU dose of Vitamin D An electrolyte energy boost - that provides a healthier, sugar-free alternative to energy drinks Sleep - a dose of melatonin that dissolves on the tongue so it can be taken even after the user climb into bed. The opportunity to serve the Latin American market with this venture into Mexico is an exciting one that is expected to accelerate the ramp up of CURE’s FDA-registered, cGMP manufacturing facility, where the Company pioneered and developed its patented CUREfilm, drug delivery platform. The Company expects to select a distribution partner for the LATAM territory in the coming months.
お知らせ • Mar 17CURE Pharmaceutical Holding Corp. Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health DisordersCURE Pharmaceutical Holding Corp. announced that it has launched a new initiative for the clinical development of psychedelic compounds such as psilocybin, LSD, and MDMA for the treatment of various mental health disorders. Utilizing CURE’s patented oral film platform CUREfilm for precision dosing, the company intends to optimize the absorption and metabolism of psychedelic actives targeting clinical efficacy of both macrodosing and microdosing treatment regimens. CURE will use its DEA Schedule 1 license and cGMP-certified and FDA-registered facility providing a United States footprint for anticipated commercialization. Ongoing research, which has been active for decades, continues to showcase a growing body of evidence in support of psychedelics as effective treatments for mental health disorders such as depression, PTSD, addiction disorders, obsessive compulsive disorder, and anxiety.
お知らせ • Mar 12CURE Pharmaceutical Holding Corp. Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral ApplicationsCURE Pharmaceutical Holding Corp. announced that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline. The first is an antiviral clinical development program where the Company will look to load a known active pharmaceutical ingredient (API) onto its patented drug delivery platform CUREfilm®, CURE’s oral thin film platform that optimizes the absorption and metabolism of therapeutic actives. The second pipeline product addition uses a similar bioequivalence approach where the Company will formulate the delivery of a known anti-seizure API for both adult and pediatric indications. These programs will leverage existing pre-clinical/clinical safety and toxicity data to develop orally bioavailable products and expand the Company’s pharmaceutical research & development efforts toward building a specialty pharmaceutical pipeline. CURE recently announced the start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Sildenafil Citrate oral dispersible product known as CUREfilm® blue. This application, as well as these additional pipeline products are anticipated to be initiated via the 505(b)(2) drug approval pathway, with both Academic and Industry partnerships anticipated to facilitate the most intuitive path to commercialization.
お知らせ • Feb 24CURE Pharmaceutical Announces the Initiation of Clinical Trials for Erectile Dysfunction Product Curefilm Blue™CURE Pharmaceutical Holding Corp. announced this week’s start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). This application has been initiated via the 505(b)(2) drug approval pathway, and is in continuation of FDA-provided feedback in support of CURE’s clinical development plans for its CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience. The global erectile dysfunction drug market is projected to reach approximately $6.6 Billion by 2025, at a CAGR of 6.0% over the five-year forecasted period with sildenafil representing a majority of the market according to a report by QYR Research.
お知らせ • Feb 12CURE Pharmaceutical Holdings Announces Promotions and Additions to Board of DirectorsCURE Pharmaceutical Holdings announced updates and additions to its Board of Directors. After a dedicated run as Chairman of the Board, William Yuan is stepping down and will continue to serve the Company as an advisor and Chairman Emeritus. Rubén José King-Shaw Jr, a highly qualified and respected member of the Board, has been selected to step into that role. Mr. King-Shaw brings with him three decades of executive leadership experience in the healthcare technology and private equity sectors. He recently served on the board of Atlanta-based Cotiviti Holdings Inc. and currently serves on the board of US Retina of Denver, CO. He is currently serving as Chief Strategy Officer of Steward Health Care Systems, LLC, and has held C-suite positions with leading private companies including Neighborhood Health Partnership Inc. and JMH Health Plan.
お知らせ • Jan 06Cure Pharmaceutical Receives Fda Approval for Its Ind Application for Erectile Dysfunction Product Curefilm Blue™CURE Pharmaceutical Holding Corp. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience.
お知らせ • Oct 30CURE Pharmaceutical Holding Corp. Appoints Nancy Duitch to the BoardEffective October 23, 2020, the Board of Directors of Cure Pharmaceutical Holding Corp. (the “Company”), appointed Nancy Duitch as a new member of the Board pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 23, 2020 (the “Merger Agreement”), by and among the Company, Cure Labs Inc., and The Sera Labs Inc., and Nancy Duitch, in her capacity as the security holders representative. On October 5, 2020, as a condition to closing the Merger, the Company entered into an employment agreement with Ms. Duitch as Chief Strategy Officer-Wellness of the Company.
お知らせ • Oct 06+ 1 more updateCURE Pharmaceutical Holding Corp. (OTCPK:CURR) completed the acquisition of Sera Labs, Inc.CURE Pharmaceutical Holding Corp. (OTCPK:CURR) entered into a non-binding Memorandum of Understanding to acquire Sera Labs, Inc. for $44 million on July 27, 2020. CURE Pharmaceutical Holding Corp. entered into a definitive agreement to acquire Sera Labs, Inc. on September 23, 2020. The consideration is comprised of $19 million in CURE stock at a valuation of $2.75 per share and $1 million in cash, with an initial, additional commitment of $4 million for working capital in support of accelerating Sera Labs’ growth. The transaction also includes the potential for an earn out of up to $20 million in CURE stock at a valuation of $3.34 per share within two years of the closing of the acquisition, contingent upon Sera Labs achieving certain key financial targets. Pursuant to the transaction, Sera Labs will become a wholly-owned subsidiary of the company. In connection with the execution of the Memorandum of Understanding, the company will loan to Sera Labs $500,000 in exchange for the issuance of a secured promissory note, with the right to take a future advance of an additional $1,000,000 if the Proposed Acquisition does not close by September 1, 2020. The Promissory Note is secured by certain assets of Sera Labs. The Promissory Note bears an interest rate of 9% per annum and has a maturity date of December 31, 2020. The outstanding principal amount and any unpaid accrued interest may be prepaid at any time, provided that Sera Labs gives written notice to the company at least 15 days in advance of the prepayment. The Promissory Note provides that, upon the occurrence of any Event of Default, the company may accelerate the Promissory Note by written notice to Sera Labs, with the principal amount plus all accrued but unpaid interest becoming immediately due and payable in cash, except that, upon the occurrence of a Bankruptcy Event, no notice shall be required and the Outstanding Balance shall become immediately and automatically due and payable. The Promissory Note further provides that if a merger transaction is effected between the company and Sera Labs pursuant to the terms of a definitive merger agreement, the outstanding principal amount shall be credited to marketing and growth funds, as to be described in such definitive merger agreement. Sera Labs and CURE teams will be joining forces and Nancy Duitch, founder and Chief Executive Officer of Sera Labs, will continue leadership at the helm of Sera Labs and will also serve as a key member of CURE‘s leadership team upon closing of the transaction. The transaction is expected to close, subject to a definitive agreement and customary closing conditions, by the fourth quarter of 2020. As of September 24, 2020, the transaction is expected to close in early October. CURE Pharmaceutical Holding Corp. (OTCPK:CURR) completed the acquisition of Sera Labs, Inc. on October 2, 2020. At the Effective Time of the Merger, all issued and outstanding shares of the capital stock of Sera Labs were converted into the right to receive, subject to customary adjustments, an aggregate of approximately $1 million in cash and up to 6,.9 million shares of the CURE Pharmaceutical Holding Corp.'s common stock. On October 1, 2020, CURE Pharmaceutical and Sera Labs entered into a Waiver of closing condition, pursuant to which the CURE Pharmaceutical's obligation to pay the upfront payment at the effective time was extended to October 13, 2020. Pursuant to the Merger Agreement, Sera Labs security holders are also entitled to receive up to 5.9 million shares of the CURE Pharmaceutical's common stock based on the achievement of certain sales milestones up to an aggregate maximum amount of $20 million as set forth in the merger agreement. In connection with the merger the transaction is subject to lock-Up agreement, escrow agreement, ancillary agreement and employment agreement. The transaction is also subject to CURE Pharmaceutical's stock holders. Brent A. Reinke from Musick Peeler & Garrett LLP served as a legal advisor for CURE Pharmaceutical Holding Corp. Rick Citron from Citron & Deutsch served as a legal advisor for Sera Labs, Inc. and Nancy Duitch.
お知らせ • Oct 01CURE Pharmaceutical Holding Corp. announced that it has received $1 million in funding from Ionic Ventures, LLCCURE Pharmaceutical Holding Corp. (OTCPK:CURR) announced a private placement of demand secured promissory note for principal amount of $1,100,000 receiving gross proceeds of $1,000,000 on September 25, 2020. The transaction included participation from Ionic Ventures, LLC. The promissory note are issued at $100,000 original discount. The notes bears no interest rate and is subject to payment on demand of the investor after the earlier of either the initial date after September 25, 2020 of any offering of securities by the company with gross proceeds of at least $1,000,000 or October 31, 2020.
お知らせ • Sep 30Cure Pharmaceutical Holding Corp. to Enter into an Employment Agreement with Nancy Duitch in Her Capacity as Chief Strategy Officer - WellnessOn September 23, 2020, Cure Pharmaceutical Holding Corp. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization by and among the Company, Cure Labs Inc., a Delaware corporation and a wholly owned, subsidiary of the Company (“Merger Sub”), The Sera Labs Inc., a Delaware corporation (“Sera Labs”), and Nancy Duitch, in her capacity as the security holders representative. The Merger Agreement provides for the acquisition of Sera Labs by the Company through the merger of Merger Sub with and into Sera Labs, with Sera Labs surviving as a wholly owned, subsidiary of the Company (the “Merger”). The Merger Agreement also contemplates that at the Effective Time the Company will enter into an employment agreement with Nancy Duitch in her capacity as Chief Strategy Officer - Wellness of the Company and Chief Executive Officer of Sera Labs.
お知らせ • Sep 26Cure Pharmaceutical Holding Corp. Announces Appointments to its BoardCure Pharmaceutical Holding Corp. at its AGM held on September 23, 2020 announced appointment of Gene Salkind and Lauren Chung to the Board of Directors, each for a one-year term ending at the Annual Meeting of Stockholders to be held in 2021 and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal.